Rejuveron Life Sciences AG in Zurich, which is developing medicines for diseases of aging, said on 13 September that it closed a $75m dual tranche series B equity and convertible loan financing. Rejuveron plans to expand and advance its pipeline and, based on a recently acquired stake in brain synapse regeneration-focused Boost Neuroscience with a presence in the Middle East, it will establish an office in Abu Dhabi, United Arab Emirates. The company has two programs in the clinic – a small molecule approach to regenerate endogenous stem cells in a Phase I/IIa trial for the treatment of retinitis pigmentosa – and a novel drug combination therapy in Phase Ib for sarcopenia. Rejuvenate Biomed NV, the Rejuveron subsidiary advancing the sarcopenia asset, raised €15.7m ($18.2m) in series B funding in October 2021. (Also see "Finance Watch: 2021 Biopharma VC Funding Tops Full-Year 2020 Total" - Scrip, 19 October, 2021.)

Finance Watch: ReCode’s Series B Mega-Round Grows Again With $50m Boost

DalCor Raises $80m For Dalcetrapib Confirmatory Trial

More from Financing

More from Business